Bisphosphonates may reduce fracture risk in patients with metastatic hormone-sensitive prostate cancer

According to an analysis of data from the phase II/III STAMPEDE trial—presented during the 2023 American Urological Association Annual Meeting—bisphosphonates significantly reduced fracture risk (64%) in patients with metastatic hormone-sensitive prostate cancer (HR, 0.36; 95% CI, 0.22-0.57, P <.0005). However, there was not a significant risk reduction among patients with non-metastatic disease (HR, 0.67; 95% CI, 0.32-1.39; P = .28).